Ruvimbo Zimunya

Ruvimbo Zimunya

Auto-generated profile, based on publicly available information

Ruvimbo Zimunya

Department of Public Health, Anderson Centre for Autism, New York, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JOHN KYALO MUTHUKAJOHN KYALO MUTHUKA
JOHN KYALO MUTHUKA
COChrisphine Onyango
Chrisphine Onyango
JNJapheth Nzioki
Japheth Nzioki
LCLucy Chebungei
Lucy Chebungei
RZRuvimbo Zimunya
Ruvimbo Zimunya
RNRosemary Nabaweesi
Rosemary Nabaweesi
Background: Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by difficulties in social communication and restricted, repetitive behaviors emerging in early childhood. Given rising diagnostic rates and substantial lifelong impacts, accurate global prevalence estimates are essential for health policy, resource planning, and early intervention. This systematic review and meta-analysis synthesized global observational evidence to estimate ASD prevalence across world regions and examine factors influencing heterogeneity. Methods: Following PRISMA guidelines, searches were conducted in PubMed, Scopus, Web of Science, Embase, and Google Scholar for observational and registry-based studies published from 2004–2025. Twenty-two studies met inclusion criteria. Random-effects models (REML) estimated pooled global and regional prevalence. Heterogeneity was assessed using Q, I², τ², Baujat plots, and influence diagnostics. Subgroup analyses and meta-regressions evaluated moderators including geographic region, mean age, and prevalence per 1,000. Sensitivity analyses assessed model robustness. Results: The pooled global prevalence of ASD was 1.8% (95% CI: 0.8–3.7%). Substantial heterogeneity existed across studies (Q p <.001; τ = 1.64), with prediction intervals ranging from 0.05% to 37.8%. Regional estimates ranged from 0.65% in the Middle East to 3.4% in North America, though subgroup differences were not statistically significant. Meta-regression suggested significant moderation by mean age and prevalence per 1,000 (R² = 59.35%), although sensitivity analyses revealed that these effects were largely driven by one influential study. Publication bias was minimal. Conclusion: Global ASD prevalence remains around 1%–2%, consistent with contemporary epidemiological data; however, considerable heterogeneity indicates that methodological and contextual factors likely drive observed regional differences. Standardized diagnostic criteria, enhanced surveillance, and early detection systems are needed to improve global prevalence accuracy and inform public health planning.

29 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JOHN KYALO MUTHUKAJOHN KYALO MUTHUKA
JOHN KYALO MUTHUKA
RZRuvimbo Zimunya
Ruvimbo Zimunya
ASAndrina Simengwa
Andrina Simengwa
COChrisphine Onyango
Chrisphine Onyango
KOKelly Oluoch
Kelly Oluoch
DNDesire A. Nshimirimana
Desire A. Nshimirimana
This systematic review and meta-analysis aimed to estimate the overall effectiveness of ASD interventions and identify sources of heterogeneity using frequentist and Bayesian approaches. A systematic search of PubMed/MEDLINE, Embase, Web of Science, and Scopus was conducted for studies published between January 1, 2004, and April 30, 2025. Mainly, randomized controlled trial studies with extractable intervention outcomes were included. A total of 41 studies (n=3,008) were synthesized using random-effects models (REML), Bayesian hierarchical modeling, meta-regression, and sensitivity analyses following PRISMA guidelines. The pooled random-effects estimate showed a significant positive effect of ASD interventions (effect size = 0.506, 95% CI: 0.392–0.619; z = 8.72, p < .001), corresponding to an estimated success proportion of 62% (95% CI: 59%–65%). Heterogeneity was substantial (Q□(40) = 238.78, p < .001; I² = 82.45%; τ² = 0.069, 95% CI: 0.028–0.137; τ = 0.262), with H² = 5.70 and a wide prediction interval (−0.020 to 1.031), indicating strong between-study variability. Bayesian meta-analysis confirmed a comparable effect (posterior mean = 0.619, 95% CrI: 0.592–0.646), with τ = 0.273 and I² ≈ 82.5%, and MCMC diagnostics showed stable convergence (R-hat ≈ 1.00). Publication bias analyses indicated significant funnel plot asymmetry (Egger-type regression: z = 3.429, p < .001; weighted regression: t = 9.573, p < .001), while rank correlation was non-significant (τ = −0.178, p = .103). Trim-and-fill analysis imputed 10 studies, reducing the pooled effect to 0.374 (95% CI: 0.258–0.491; τ = 0.338), though the effect remained significant (p < .001). Sensitivity analyses excluding influential studies yielded a stable effect (0.505, 95% CI: 0.401–0.609), with persistent heterogeneity (I² = 75.49%; Q□(38) = 190.21, p < .001; τ² = 0.043). Subgroup analyses showed highest effects for digital/technology-based interventions (0.672; 67%; I² = 0%), followed by nutritional (0.635; 64%; I² = 73.81%), behavioral (0.630; 63%; I² = 74.78%), and pharmacological (0.627; 63%; I² = 0%) interventions, while physical/occupational therapies showed lower effects (0.523; 52%; I² = 63.35%) and combined interventions showed borderline effects (0.593; 59%; I² = 19.96%); subgroup differences were significant (Q□5) = 22.63, p < .001). Regional effects were similar and non-significant (Q□(2) = 0.73, p = .694): North America (0.619; I² = 84.21%), Europe (0.626; I² = 62.34%), and Asia (0.659; I² = 0%). Age at intervention onset did not significantly moderate effects (Q□(5) = 0.98, p = .964), although variability was observed across children, adolescents, adults, and toddlers. Meta-regression identified significant moderators including intervention context (Q□= 18.159, p = .020), outcome domain (Q□= 19.588, p = .003), age at start (Q□= 17.795, p = .003), and intervention category (Q□= 31.714, p < .001), while follow-up duration and intervention duration were not significant. Bayesian subgroup analyses confirmed robustness, with strongest evidence for pharmacological (BF → ∞), behavioral (BF ≈ 832.50), and digital interventions (BF ≈ 30.92). In conclusion, ASD interventions demonstrate a moderate and statistically significant overall effect (∼0.50–0.62), with substantial heterogeneity driven primarily by intervention type, context, and participant characteristics, and findings were consistent across frequentist, Bayesian, and sensitivity analyses, supporting robust but context-dependent effectiveness.